Baseline autoantibodies preferentially impact abatacept efficacy in patients with rheumatoid arthritis who are biologic naïve: 6-month results from a real-world, international, prospective study
about
Real-world predictors of 12-month intravenous abatacept retention in patients with rheumatoid arthritis in the ACTION observational study.Abatacept blocks anti-citrullinated protein antibody and rheumatoid factor mediated cytokine production in human macrophages in IDO-dependent manner.Response to baricitinib based on prior biologic use in patients with refractory rheumatoid arthritis.
P2860
Baseline autoantibodies preferentially impact abatacept efficacy in patients with rheumatoid arthritis who are biologic naïve: 6-month results from a real-world, international, prospective study
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh
2017年學術文章
@zh-hant
name
Baseline autoantibodies prefer ...... ternational, prospective study
@en
type
label
Baseline autoantibodies prefer ...... ternational, prospective study
@en
prefLabel
Baseline autoantibodies prefer ...... ternational, prospective study
@en
P2093
P2860
P1433
P1476
Baseline autoantibodies prefer ...... ternational, prospective study
@en
P2093
Alain Cantagrel
Christiane Rauch
Coralie Poncet
Hanns-Martin Lorenz
Hubert G Nüßlein
Manuela Le Bars
Melanie Chartier
Rieke Alten
Xavier Mariette
P2860
P304
P356
10.1136/RMDOPEN-2016-000345
P577
2017-02-13T00:00:00Z